MT201 Adecatumumab A Fully Human Antibody to Ep-CAM

168 Pages·2010·11.15 MB·English

Micromet, Inc.
2010 Investor & Analyst Meeting
Yale Club
New York, NY
February 10, 2010
NASDAQ: MITI
Page 2
Forward-Looking Statements
This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause actual results
to be materially different from historical results or from any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of the
Company’s product candidates, the conduct and results of future clinical trials, and plans regarding regulatory filings, future
research, discovery of new product candidates, and clinical trials and plans regarding partnering activities. Factors that may
cause actual results to differ materially include the risk that product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that we will not obtain
approval to market our products, the risks associated with reliance on outside financing to meet capital requirements, and the
risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product
candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes,"
"estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or
the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more
fully discussed in our periodic reports and other filings with the SEC.
Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet, Inc. undertakes
no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or
otherwise.
NASDAQ: MITI
Page 3
2009: Significant Progress
Reported interim data
Signed agreement MT103 achieves from ph 1 MT110 Entered into agreement
with Bayer Schering 2009 Analyst & primary endpoint in solid tumor study with Lonza for
for solid tumor BiTE Investor Event ph 2 ALL study manufacture of MT103
Q1 Q2 Q3 Q4
Signed agreement
Reported preclinical Received orphan drug with sanofi-aventis
Re-gained MT103
data showing activity designation for MT103 for solid tumor BiTE
development rights
of Erbitux and Vectibix from EMEA for ALL
from MedImmune
based BiTE antibodies
Reported new data
Re-gained MT103
on MT103 in ALL and Reported new data
commercial rights
NHL at EHA on MT103 in ALL and
from MedImmune
NHL at ASH
Strong momentum moving into 2010…
NASDAQ: MITI
Page 4
High Potential Next-Generation Antibody Pipeline
Program Target Partner Pre-clinical Phase 1 Phase 2 Pivotal / Phase 3
MT103 CD19 -- ALL
MT103 CD19 -- NHL
MT110 EpCAM -- Carcinoma
MT111 CEA Medimmune Carcinoma
-- n.d. Bayer Schering Carcinoma
-- n.d. Sanofi Aventis Carcinoma
-- CD33 -- AML
-- EGFR -- Carcinoma
NASDAQ: MITI
Page 5
BiTE® Antibodies Use Patients Own
Killer Cells to Eliminate Cancer
T Cell
Master Switch CD3
CD3
BiTE
BiTE
TAA
Tumor Associated Antigen
Tumor Cell

BiTE Antibodies Engage T Cells to Eliminate Tumors
NASDAQ: MITI
Page 6
Blinatumomab (MT103) Overview
BiTE antibody with dual specificity for CD19 and CD3
Impressive efficacy observed in patients with ALL, MCL and FL
Strong mechanistic rationale for development in DLBCL and CLL
•
Prioritized development program planned in disease settings with
significant commercial potential and high unmet need
•
3 new trials to be initiated in 2010
•
Micromet retains global commercialization rights
NASDAQ: MITI
Page 7
Blinatumomab: Broad Potential Utility in ALL
ALL
Adult Pediatric
1st Line 1st Line
MRD+ MRD- MRD+ MRD-
1ST Relapse 1st Relapse
2nd Relapse 2nd Relapse
NASDAQ: MITI
Page 8
Presenters
•
Dr. Nicola Goekbuget, Head of Study Center, Goethe University Clinic, Frankfurt,
Germany
•
Coordinator of the German multicenter study group for ALL (GMALL)
•
Scientific interest focuses clinical research in the field of ALL
•
Dr. Arend von Stackelberg, Pediatric Oncology/Hemotology, Charité - University
Clinic, Berlin, Germany
•
Study coordinator for relapsed/refractory ALL of the international BFM group
•
Clinical interests focus on pediatric acute lymphocytic leukemia
•
Dr. James Whitlock, Craig Weaver Professor of Pediatrics, Vanderbilt University
Medical Center
•
Clinical interests include the biology and treatment of acute lymphocytic leukemia
•
Holds leadership role in the Children’s Oncology Group
•
Dr. Gerhard Zugmaier, Vice President, Hematology, Micromet
•
Previously held clinical roles at Baxter and Hoffman La Roche
•
Blinatumomab Program Leader
NASDAQ: MITI
Page 9
Presenters
•
Dr. Stan Frankel, Vice President, Clinical Development, Micromet
•
20 years of oncology drug development experience in both industry and academia
•
Previously served in leadership roles at Hoffman-La Roche and Merck and Co
•
Dr. Jan Fagerberg, Senior Vice President and Chief Medical Officer, Micromet
•
More than 20 years of experience in clinical research and development of oncology drugs
•
Previously served in leadership roles at Hoffman-La Roche and Topo Target
•
Mark Reisenauer, Senior Vice President and Chief Commercial Officer, Micromet
•
More than 20 years of pharmaceutical sales and marketing experience
•
Previously served in leadership roles at Abbott and Pharmacia
•
Dr. Patrick Baeuerle, Senior Vice President and Chief Scientific Officer, Micromet
•
More than 20 years of drug discovery experience spanning both academia and industry
•
Previously headed the drug discovery activities of Tularik Inc.
NASDAQ: MITI
Page 10
Agenda
Background to ALL:
•
Adult ALL and implications of MRD: Dr. Nicola Goekbuget
•
Pediatric ALL, International BFM group perspective: Dr. Arend von
Stackelberg
•
Pediatric ALL, US perspective: Dr. Jim Whitlock
Experience and Outlook in ALL:
•
Results from phase 2 study in MRD-positive adult ALL: Dr. Gerhard
Zugmaier
•
Compassionate use in pediatric ALL: Dr. Arend von Stackelberg
•
Comprehensive blinatumomab development program in B-ALL: Dr.
Gerhard Zugmaier
NASDAQ: MITI